<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ketendo</journal-id><journal-title-group><journal-title xml:lang="ru">Клиническая и экспериментальная тиреоидология</journal-title><trans-title-group xml:lang="en"><trans-title>Clinical and experimental thyroidology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-5472</issn><issn pub-type="epub">2310-3787</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/ket12251</article-id><article-id custom-type="elpub" pub-id-type="custom">ketendo-12251</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзоры литературы</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Review of literature</subject></subj-group></article-categories><title-group><article-title>Роль аутофагии в развитии опухолей щитовидной железы, связь с активацией AKT/m-TOR сигнального пути</article-title><trans-title-group xml:lang="en"><trans-title>The role of autophagy in the thyroid tumors development, connection with the AKT/m-TOR signaling pathway activation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5269-736X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Спирина</surname><given-names>Людмила Викторовна</given-names></name><name name-style="western" xml:lang="en"><surname>Spirina</surname><given-names>Liudmila V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н.</p></bio><bio xml:lang="en"><p>MD, PhD</p></bio><email xlink:type="simple">spirinalv@oncology.tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чижевская</surname><given-names>Светлана Юрьевна</given-names></name><name name-style="western" xml:lang="en"><surname>Chizhevskaya</surname><given-names>Sventlana Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинский наук, ведущий научный сотрудник отделения опухолей головы и шеи</p></bio><bio xml:lang="en"><p>Leader Researcher, Division of Head and Neck Tumors</p></bio><email xlink:type="simple">sch@oncology.tomsk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0907-4615</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кондакова</surname><given-names>Ирина Викторовна</given-names></name><name name-style="western" xml:lang="en"><surname>Kondakova</surname><given-names>Irina V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., проф.</p></bio><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><email xlink:type="simple">kondakova@oncology.tomsk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3605-5009</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарасенко</surname><given-names>Наталья Викторовна</given-names></name><name name-style="western" xml:lang="en"><surname>Tarasenko</surname><given-names>Nataliya V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинский наук, ассистент кафедры медицинской генетики; научный сотрудник лаборатории популяционной генетики</p></bio><bio xml:lang="en"><p>Associated Professor, Medical Genetic Division; Researcher</p></bio><email xlink:type="simple">nataly.tarasenko@medgenetics.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»; «Сибирский государственный медицинский университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tomsk National Research Medical Center of the Russian Academy of Sciences; Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tomsk National Research Medical Center of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»; Сибирский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tomsk National Research Medical Center of the Russian Academy of Sciences; Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>12</day><month>02</month><year>2020</year></pub-date><volume>15</volume><issue>3</issue><fpage>110</fpage><lpage>117</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Спирина Л.В., Чижевская С.Ю., Кондакова И.В., Тарасенко Н.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Спирина Л.В., Чижевская С.Ю., Кондакова И.В., Тарасенко Н.В.</copyright-holder><copyright-holder xml:lang="en">Spirina L.V., Chizhevskaya S.Y., Kondakova I.V., Tarasenko N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.cet-endojournals.ru/jour/article/view/12251">https://www.cet-endojournals.ru/jour/article/view/12251</self-uri><abstract><p>Аутофагия является важным внутриклеточным процессом, обеспечивающим гибель и выживаемость клеток. Молекулярные механизмы развития злокачественных новообразований связаны с изменением состояния AKT/mTOR сигнального пути. При этом доказано существование защитной аутофагии как одного из механизмов прогрессирования заболевания и формирования резистентности к лечению. В обзоре описаны молекулярные механизмы развития аутофагии, ее ассоциации с ключевыми сигнальными каскадами, в частности AKT/mTOR. Значимая сигнальная молекула mTOR в составе комплекса TORC1 в этом случае не только способствует развитию опухоли, пролиферации трансформированных клеток, их уходу от апоптоза, но и развитию аутофагии.</p><p>Отмечено значение данного явления на всех этапах онкогенеза, влияющего на протеинкиназы AKT, mTOR. Показано, что в подавляющем большинстве случаев этот механизм срабатывает при прогрессировании заболевания и развитии резистентности к лечению. Развитие рака щитовидной железы, сопряженное с мутацией гена BRAF и активацией онкобелка RET, а также ответ на лечение и формирование радиойодрезистентных форм заболевания определяются молекулярными особенностями регуляции аутофагии. Учитывая противоречивость данных относительно влияния аутофагии на процессы онкогенеза, до сих пор остается неизвестной ее роль в патогенезе злокачественных опухолей данной локализации.</p></abstract><trans-abstract xml:lang="en"><p>Autophagy is an important intracellular process that supports cell death and survival. Oncogenesis is associated with a change in the AKT/mTOR signaling pathway status. At the same time, the existence of protective autophagy, as one of the mechanisms of disease progression and the formation of resistance to treatment, has been proven. The review describes the significant mechanisms of the autophagy development, its association with AKT/mTOR signaling pathway. A molecule mTOR in TORC1 complex is associated with the oncogenesis, it provides the proliferation of transformed cells, apoptosis inhibition, and to the development of autophagy.</p><p>The participation of this phenomenon at all stages of carcinogenesis, influencing on the main signal kinases: AKT, mTOR, is noted. It is shown that in most cases this mechanism is responsible for the progression of the disease and the development of resistance to treatment. The development of thyroid cancer associated with the BRAF mutation and with the activation of the RET oncoprotein, as well as with the formation of radio-resistant forms of the disease is associated with molecular peculiarities of autophagy. Given the inconsistency of this phenomenon regarding their influence on the processes of oncogenesis, its role in the development of thyroid cancer is still unknown.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак щитовидной железы</kwd><kwd>аутофагия</kwd><kwd>AKT/mTOR сигнальный каскад</kwd><kwd>BRAF</kwd><kwd>RET</kwd></kwd-group><kwd-group xml:lang="en"><kwd>thyroid cancer</kwd><kwd>autophagy</kwd><kwd>AKT/mTOR signaling pathway</kwd><kwd>BRAF</kwd><kwd>RET</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W, Kang H, Zhao Y, et al. Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J Clin Endocrinol Metab. 2017;102(2):634-643. doi: https://doi.org/10.1210/jc.2016-1999.</mixed-citation><mixed-citation xml:lang="en">Wang W, Kang H, Zhao Y, et al. Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J Clin Endocrinol Metab. 2017;102(2):634-643. doi: https://doi.org/10.1210/jc.2016-1999.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Xing M. Genetic alterations in the phosphatidylinositol-3kinase/Akt pathway in thyroid cancer. Thyroid. 2010;20(7):697-706. doi: https://doi.org/10.1089/thy.2010.1646.</mixed-citation><mixed-citation xml:lang="en">Xing M. Genetic alterations in the phosphatidylinositol-3kinase/Akt pathway in thyroid cancer. Thyroid. 2010;20(7):697-706. doi: https://doi.org/10.1089/thy.2010.1646.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Martelli AM, Evangelisti C, Chiarini F, et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling networkin cancer stem cell biology. Cancers (Basel). 2010;2(3):1576-1596. doi: https://doi.org/10.3390/cancers2031576.</mixed-citation><mixed-citation xml:lang="en">Martelli AM, Evangelisti C, Chiarini F, et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling networkin cancer stem cell biology. Cancers (Basel). 2010;2(3):1576-1596. doi: https://doi.org/10.3390/cancers2031576.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol. 2010;22(2):132-139. doi: https://doi.org/10.1016/j.ceb.2009.12.004.</mixed-citation><mixed-citation xml:lang="en">Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol. 2010;22(2):132-139. doi: https://doi.org/10.1016/j.ceb.2009.12.004.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wei WJ, Hardin H, Luo QY. Targeting autophagy in thyroid cancers. Endocr Relat Cancer. 2019;26(4):R181-R194. doi: https://doi.org/10.1530/ERC-18-0502.</mixed-citation><mixed-citation xml:lang="en">Wei WJ, Hardin H, Luo QY. Targeting autophagy in thyroid cancers. Endocr Relat Cancer. 2019;26(4):R181-R194. doi: https://doi.org/10.1530/ERC-18-0502.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Faustino A, Couto JP, Populo H, et al. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97(7):E1139-1149. doi: https://doi.org/10.1210/jc.2011-2748.</mixed-citation><mixed-citation xml:lang="en">Faustino A, Couto JP, Populo H, et al. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97(7):E1139-1149. doi: https://doi.org/10.1210/jc.2011-2748.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Netea-Maier RT, Klück V, Plantinga TS, Smit JW. Autophagy in thyroid cancer: present knowledge and future perspectives. Front Endocrinol (Lausanne). 2015;6:22. doi: https://doi.org/10.3389/fendo.2015.00022.</mixed-citation><mixed-citation xml:lang="en">Netea-Maier RT, Klück V, Plantinga TS, Smit JW. Autophagy in thyroid cancer: present knowledge and future perspectives. Front Endocrinol (Lausanne). 2015;6:22. doi: https://doi.org/10.3389/fendo.2015.00022.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Eskelinen EL. Autophagy: supporting cellular and organismal homeostasis by self-eating. Int J Biochem Cell Biol. 2019;111:1-10. doi: https://doi.org/10.1016/j.biocel.2019.03.010.</mixed-citation><mixed-citation xml:lang="en">Eskelinen EL. Autophagy: supporting cellular and organismal homeostasis by self-eating. Int J Biochem Cell Biol. 2019;111:1-10. doi: https://doi.org/10.1016/j.biocel.2019.03.010.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Спирина Л.В., Чижевская С.Ю., Кондакова И.В. Экспрессия транскрипционных, ростовых факторов и компонентов AKT/m-TOR сигнального пути в ткани папиллярного рака щитовидной железы // Проблемы эндокринологии. – 2018. – Т.64. – №4. – С. 208-215. [Spirina LV, Chigevskaya SYu, Kondakova IV. Expression of transcription, growth factors and components of AKT/m-TOR signaling pathway in papillary thyroid cancers. Problemy endokrinologii. 2018;64(4):208-215. (In Russ.)] doi: https://doi.org/10.14341/probl9310.</mixed-citation><mixed-citation xml:lang="en">Спирина Л.В., Чижевская С.Ю., Кондакова И.В. Экспрессия транскрипционных, ростовых факторов и компонентов AKT/m-TOR сигнального пути в ткани папиллярного рака щитовидной железы // Проблемы эндокринологии. – 2018. – Т.64. – №4. – С. 208-215. [Spirina LV, Chigevskaya SYu, Kondakova IV. Expression of transcription, growth factors and components of AKT/m-TOR signaling pathway in papillary thyroid cancers. Problemy endokrinologii. 2018;64(4):208-215. (In Russ.)] doi: https://doi.org/10.14341/probl9310.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Li YJ, Lei YH, Yao N, et al. Autophagy and multidrug resistance in cancer. Chin J Cancer. 2017;36(1):52. doi: https://doi.org/10.1186/s40880-017-0219-2.</mixed-citation><mixed-citation xml:lang="en">Li YJ, Lei YH, Yao N, et al. Autophagy and multidrug resistance in cancer. Chin J Cancer. 2017;36(1):52. doi: https://doi.org/10.1186/s40880-017-0219-2.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie. 2008; 90(2):313-323. doi: https://doi.org/10.1016/j.biochi.2007.08.014.</mixed-citation><mixed-citation xml:lang="en">Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie. 2008; 90(2):313-323. doi: https://doi.org/10.1016/j.biochi.2007.08.014.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshii SR, Mizushima N. Monitoring and measuring autophagy. Int J Mol Sci. 2017;18(9):pii:E1865. doi: https://doi.org/10.3390/ijms18091865.</mixed-citation><mixed-citation xml:lang="en">Yoshii SR, Mizushima N. Monitoring and measuring autophagy. Int J Mol Sci. 2017;18(9):pii:E1865. doi: https://doi.org/10.3390/ijms18091865.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Satoo K, Noda NN, Kumeta H, et al. The structure of Atg4BLC3 complex reveals the mechanism of LC3 processing and delipidation during autophagy. EMBO J. 2009;28(9):1341-1350. doi: https://doi.org/10.1038/emboj.2009.80.</mixed-citation><mixed-citation xml:lang="en">Satoo K, Noda NN, Kumeta H, et al. The structure of Atg4BLC3 complex reveals the mechanism of LC3 processing and delipidation during autophagy. EMBO J. 2009;28(9):1341-1350. doi: https://doi.org/10.1038/emboj.2009.80.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Morell C, Bort A, Vara-Ciruelos D, et al. Up-regulated expression of LAMP2 and autophagy activity during neuroendocrine differentiation of prostate cancer LNCaP cells. PLoS One. 2016;11(9): e0162977. doi: https://doi.org/10.1371/journal.pone.0162977.</mixed-citation><mixed-citation xml:lang="en">Morell C, Bort A, Vara-Ciruelos D, et al. Up-regulated expression of LAMP2 and autophagy activity during neuroendocrine differentiation of prostate cancer LNCaP cells. PLoS One. 2016;11(9): e0162977. doi: https://doi.org/10.1371/journal.pone.0162977.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pasquier B. Autophagy inhibitors. Cell Mol Life Sci. 2016;73(5): 985-1001. doi: https://doi.org/10.1007/s00018-015-2104-y.</mixed-citation><mixed-citation xml:lang="en">Pasquier B. Autophagy inhibitors. Cell Mol Life Sci. 2016;73(5): 985-1001. doi: https://doi.org/10.1007/s00018-015-2104-y.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J, Xia H, Kim M, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011;147(1):223-234. doi: https://doi.org/10.1016/j.cell.2011.08.037.</mixed-citation><mixed-citation xml:lang="en">Liu J, Xia H, Kim M, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011;147(1):223-234. doi: https://doi.org/10.1016/j.cell.2011.08.037.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Shao S, Li S, Qin Y, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int J Oncol. 2014;44(5):1661-1668. doi: https://doi.org/10.3892/ijo.2014.2313.</mixed-citation><mixed-citation xml:lang="en">Shao S, Li S, Qin Y, et al. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Int J Oncol. 2014;44(5):1661-1668. doi: https://doi.org/10.3892/ijo.2014.2313.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Byun S, Lee E, Lee KW. Therapeutic implications of autophagy inducers in immunological disorders, infection, and cancer. Int J Mol Sci. 2017;18(9):1959. doi: https://doi.org/10.3390/ijms18091959.</mixed-citation><mixed-citation xml:lang="en">Byun S, Lee E, Lee KW. Therapeutic implications of autophagy inducers in immunological disorders, infection, and cancer. Int J Mol Sci. 2017;18(9):1959. doi: https://doi.org/10.3390/ijms18091959.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Nagelkerke A, Sweep FC, Geurts-Moespot A, et al. Therapeutic targeting of autophagy in cancer. Part I: molecular pathways controlling autophagy. Semin Cancer Biol. 2015;31:89-98. doi: https://doi.org/10.1016/j.semcancer.2014.05.004.</mixed-citation><mixed-citation xml:lang="en">Nagelkerke A, Sweep FC, Geurts-Moespot A, et al. Therapeutic targeting of autophagy in cancer. Part I: molecular pathways controlling autophagy. Semin Cancer Biol. 2015;31:89-98. doi: https://doi.org/10.1016/j.semcancer.2014.05.004.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hardie DG. AMPK and autophagy get connected. EMBO J. 2011;30(4):634-635. doi: https://doi.org/10.1038/emboj.2011.12.</mixed-citation><mixed-citation xml:lang="en">Hardie DG. AMPK and autophagy get connected. EMBO J. 2011;30(4):634-635. doi: https://doi.org/10.1038/emboj.2011.12.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou YY, Li Y, Jiang WQ, Zhou LF. MAPK/JNK signalling: a potential autophagy regulation pathway. Biosci Rep. 2015;35(3): e00199. doi: https://doi.org/10.1042/BSR20140141.</mixed-citation><mixed-citation xml:lang="en">Zhou YY, Li Y, Jiang WQ, Zhou LF. MAPK/JNK signalling: a potential autophagy regulation pathway. Biosci Rep. 2015;35(3): e00199. doi: https://doi.org/10.1042/BSR20140141.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H, Wang L, Cao L, et al. Inhibition of autophagy potentiates the anti-metastasis effect of phenethylisothiocyanate through JAK2/STAT3 pathway in lung cancer cells. Mol Carcinog. 2018;57(4):522-535. doi: https://doi.org/10.1002/mc.22777.</mixed-citation><mixed-citation xml:lang="en">Wang H, Wang L, Cao L, et al. Inhibition of autophagy potentiates the anti-metastasis effect of phenethylisothiocyanate through JAK2/STAT3 pathway in lung cancer cells. Mol Carcinog. 2018;57(4):522-535. doi: https://doi.org/10.1002/mc.22777.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Huang S, Qi P, Zhang T, et al. The HIF 1α/miR 224 3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia induced protective autophagy in glioblastoma and astrocytoma. Oncol Rep. 2019;41(3):1759-1768. doi: https://doi.org/10.3892/or.2018.6929.</mixed-citation><mixed-citation xml:lang="en">Huang S, Qi P, Zhang T, et al. The HIF 1α/miR 224 3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia induced protective autophagy in glioblastoma and astrocytoma. Oncol Rep. 2019;41(3):1759-1768. doi: https://doi.org/10.3892/or.2018.6929.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez-Outschoorn UE, Trimmer C, Lin Z, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle. 2010;9(17):3515-3533. doi: https://doi.org/10.4161/cc.9.17.12928.</mixed-citation><mixed-citation xml:lang="en">Martinez-Outschoorn UE, Trimmer C, Lin Z, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle. 2010;9(17):3515-3533. doi: https://doi.org/10.4161/cc.9.17.12928.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Capizzi M, Strappazzon F, Cianfanelli V, et al. MIR7-3HG, a MYC-dependent modulator of cell proliferation, inhibits autophagy by a regulatory loop involving AMBRA1. Autophagy. 2017;13(3): 554-566. doi: https://doi.org/10.1080/15548627.2016.1269989.</mixed-citation><mixed-citation xml:lang="en">Capizzi M, Strappazzon F, Cianfanelli V, et al. MIR7-3HG, a MYC-dependent modulator of cell proliferation, inhibits autophagy by a regulatory loop involving AMBRA1. Autophagy. 2017;13(3): 554-566. doi: https://doi.org/10.1080/15548627.2016.1269989.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mrakovcic M, Bohner L, Hanisch M, Fröhlich LF. Epigenetic targeting of autophagy via HDAC inhibition in tumor cells: role of p53. Int J Mol Sci. 2018;19(12). pii: E3952. doi: https://doi.org/10.3390/ijms19123952.</mixed-citation><mixed-citation xml:lang="en">Mrakovcic M, Bohner L, Hanisch M, Fröhlich LF. Epigenetic targeting of autophagy via HDAC inhibition in tumor cells: role of p53. Int J Mol Sci. 2018;19(12). pii: E3952. doi: https://doi.org/10.3390/ijms19123952.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Parys JB, Decuypere JP, Bultynck G. Role of the inositol 1,4,5-trisphosphate receptor/Ca2+-release channel in autophagy. Cell Commun Signal. 2012;10(1):17. doi: https://doi.org/10.1186/1478-811X-10-17.</mixed-citation><mixed-citation xml:lang="en">Parys JB, Decuypere JP, Bultynck G. Role of the inositol 1,4,5-trisphosphate receptor/Ca2+-release channel in autophagy. Cell Commun Signal. 2012;10(1):17. doi: https://doi.org/10.1186/1478-811X-10-17.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Pandurangan AK, Ismail S, Esa NM, Munusamy MA. Inositol-6 phosphate inhibits the mTOR pathway and induces autophagy-mediated death in HT-29 colon cancer cells. Arch Med Sci. 2018; 14(6):1281-1288. doi: https://doi.org/10.5114/aoms.2018.76935.</mixed-citation><mixed-citation xml:lang="en">Pandurangan AK, Ismail S, Esa NM, Munusamy MA. Inositol-6 phosphate inhibits the mTOR pathway and induces autophagy-mediated death in HT-29 colon cancer cells. Arch Med Sci. 2018; 14(6):1281-1288. doi: https://doi.org/10.5114/aoms.2018.76935.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Russo R, Berliocchi L, Adornetto A, et al. Calpain-mediated cleavage of Beclin-1 and autophagy deregulation following retinal ischemic injury in vivo. Cell Death Dis. 2011;2(4):e144. doi: https://doi.org/10.1038/cddis.2011.29.</mixed-citation><mixed-citation xml:lang="en">Russo R, Berliocchi L, Adornetto A, et al. Calpain-mediated cleavage of Beclin-1 and autophagy deregulation following retinal ischemic injury in vivo. Cell Death Dis. 2011;2(4):e144. doi: https://doi.org/10.1038/cddis.2011.29.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Yousefi S, Perozzo R, Schmid I, et al. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol. 2006;8(10):1124-1132. doi: https://doi.org/10.1038/ncb1482.</mixed-citation><mixed-citation xml:lang="en">Yousefi S, Perozzo R, Schmid I, et al. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol. 2006;8(10):1124-1132. doi: https://doi.org/10.1038/ncb1482.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Xu J, Patel NH, Saleh T, et al. Differential radiation sensitivity in p53 wild-type and p53-deficient tumor cells associated with senescence but not apoptosis or (nonprotective) autophagy. Radiat Res. 2018;190(5):538-557. doi: https://doi.org/10.1667/RR15099.1.</mixed-citation><mixed-citation xml:lang="en">Xu J, Patel NH, Saleh T, et al. Differential radiation sensitivity in p53 wild-type and p53-deficient tumor cells associated with senescence but not apoptosis or (nonprotective) autophagy. Radiat Res. 2018;190(5):538-557. doi: https://doi.org/10.1667/RR15099.1.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Feng Z. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol. 2010; 2(2):a001057. doi: https://doi.org/10.1101/cshperspect.a001057.</mixed-citation><mixed-citation xml:lang="en">Feng Z. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol. 2010; 2(2):a001057. doi: https://doi.org/10.1101/cshperspect.a001057.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Su M, Mei Y, Sinha S. Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol. 2013;2013:102735. doi: https://doi.org/10.1155/2013/102735.</mixed-citation><mixed-citation xml:lang="en">Su M, Mei Y, Sinha S. Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol. 2013;2013:102735. doi: https://doi.org/10.1155/2013/102735.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Wang BJ, Zheng WL, Feng NN, et al. The effects of autophagy and PI3K/AKT/m-TOR signaling pathway on the cell-cycle arrest of rats primary sertoli cells induced by zearalenone. Toxins (Basel). 2018;10(10):398. doi: https://doi.org/10.3390/toxins10100398.</mixed-citation><mixed-citation xml:lang="en">Wang BJ, Zheng WL, Feng NN, et al. The effects of autophagy and PI3K/AKT/m-TOR signaling pathway on the cell-cycle arrest of rats primary sertoli cells induced by zearalenone. Toxins (Basel). 2018;10(10):398. doi: https://doi.org/10.3390/toxins10100398.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Yang F, Wang F, Liu Y, et al. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells. Life Sci. 2018;213:149-157. doi: https://doi.org/10.1016/j.lfs.2018.10.034.</mixed-citation><mixed-citation xml:lang="en">Yang F, Wang F, Liu Y, et al. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells. Life Sci. 2018;213:149-157. doi: https://doi.org/10.1016/j.lfs.2018.10.034.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Prescott JD, Zeiger MA. The RET oncogene in papillary thyroid carcinoma. Cancer. 2015;121(13):2137-2146. doi: https://doi.org/10.1002/cncr.29044.</mixed-citation><mixed-citation xml:lang="en">Prescott JD, Zeiger MA. The RET oncogene in papillary thyroid carcinoma. Cancer. 2015;121(13):2137-2146. doi: https://doi.org/10.1002/cncr.29044.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Jeong SH, Hong HS, Lee EH, et al. Analysis of RAS mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population. Endocrinol Diabetes Metab. 2018;1(4):e00040. doi: https://doi.org/10.1002/edm2.40.</mixed-citation><mixed-citation xml:lang="en">Jeong SH, Hong HS, Lee EH, et al. Analysis of RAS mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population. Endocrinol Diabetes Metab. 2018;1(4):e00040. doi: https://doi.org/10.1002/edm2.40.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Fisher KE, Jani JC, Fisher SB, et al. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res. 2013;185(1):217-224. doi: https://doi.org/10.1016/j.jss.2013.05.003.</mixed-citation><mixed-citation xml:lang="en">Fisher KE, Jani JC, Fisher SB, et al. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res. 2013;185(1):217-224. doi: https://doi.org/10.1016/j.jss.2013.05.003.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Raman P, Koenig RJ. Pax-8-PPAR-γ fusion protein in thyroid carcinoma. Nat Rev Endocrinol. 2014;10(10):616-623. doi: https://doi.org/10.1038/nrendo.2014.115.</mixed-citation><mixed-citation xml:lang="en">Raman P, Koenig RJ. Pax-8-PPAR-γ fusion protein in thyroid carcinoma. Nat Rev Endocrinol. 2014;10(10):616-623. doi: https://doi.org/10.1038/nrendo.2014.115.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrari SM, Fallahi P, Politti U, et al. Molecular targeted therapies of aggressive thyroid cancer. Front Endocrinol (Lausanne). 2015; 6:176. doi: https://doi.org/10.3389/fendo.2015.00176.</mixed-citation><mixed-citation xml:lang="en">Ferrari SM, Fallahi P, Politti U, et al. Molecular targeted therapies of aggressive thyroid cancer. Front Endocrinol (Lausanne). 2015; 6:176. doi: https://doi.org/10.3389/fendo.2015.00176.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Gule MK, Chen Y, Sano D, et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res. 2011;17(8): 2281-2291. doi: https://doi.org/10.1158/1078-0432.CCR-10-2762.</mixed-citation><mixed-citation xml:lang="en">Gule MK, Chen Y, Sano D, et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res. 2011;17(8): 2281-2291. doi: https://doi.org/10.1158/1078-0432.CCR-10-2762.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Yang M, Bai L, Yu W, et al. Expression of autophagy-associated proteins in papillary thyroid carcinoma. Oncol Lett. 2017;14(1): 411-415. doi: https://doi.org/10.3892/ol.2017.6101.</mixed-citation><mixed-citation xml:lang="en">Yang M, Bai L, Yu W, et al. Expression of autophagy-associated proteins in papillary thyroid carcinoma. Oncol Lett. 2017;14(1): 411-415. doi: https://doi.org/10.3892/ol.2017.6101.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Strohecker AM, White E. Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. Cancer Discov. 2014; 4(7):766-772. doi: https://doi.org/10.1158/2159-8290.CD-14-0196.</mixed-citation><mixed-citation xml:lang="en">Strohecker AM, White E. Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. Cancer Discov. 2014; 4(7):766-772. doi: https://doi.org/10.1158/2159-8290.CD-14-0196.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Morani F, Titone R, Pagano L, et al. Autophagy and thyroid carcinogenesis: genetic and epigenetic links. Endocr Relat Cancer. 2013;21(1):R13-29. doi: https://doi.org/10.1530/ERC-13-0271.</mixed-citation><mixed-citation xml:lang="en">Morani F, Titone R, Pagano L, et al. Autophagy and thyroid carcinogenesis: genetic and epigenetic links. Endocr Relat Cancer. 2013;21(1):R13-29. doi: https://doi.org/10.1530/ERC-13-0271.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Nozima BH, Mendes TB, Pereira GJ, et al. FAM129A regulates autophagy in thyroid carcinomas in an oncogene-dependent manner. Endocr Relat Cancer. 2019;26(1):227-238. doi: https://doi.org/10.1530/ERC-17-0530.</mixed-citation><mixed-citation xml:lang="en">Nozima BH, Mendes TB, Pereira GJ, et al. FAM129A regulates autophagy in thyroid carcinomas in an oncogene-dependent manner. Endocr Relat Cancer. 2019;26(1):227-238. doi: https://doi.org/10.1530/ERC-17-0530.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Yi H, Long B, Ye X, et al. Autophagy: a potential target for thyroid cancer therapy (Review). Mol Clin Oncol. 2014;2(5):661-665. doi: https://doi.org/10.3892/mco.2014.305.</mixed-citation><mixed-citation xml:lang="en">Yi H, Long B, Ye X, et al. Autophagy: a potential target for thyroid cancer therapy (Review). Mol Clin Oncol. 2014;2(5):661-665. doi: https://doi.org/10.3892/mco.2014.305.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Robbins HL, Hague A. The PI3K/Akt pathway in tumors of endocrine tissues. Front Endocrinol (Lausanne). 2016;6:188. doi: https://doi.org/10.3389/fendo.2015.00188.</mixed-citation><mixed-citation xml:lang="en">Robbins HL, Hague A. The PI3K/Akt pathway in tumors of endocrine tissues. Front Endocrinol (Lausanne). 2016;6:188. doi: https://doi.org/10.3389/fendo.2015.00188.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Dodd KM, Yang J, Shen MH, et al. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene. 2015;34(17):2239-2250. doi: https://doi.org/10.1038/onc.2014.164.</mixed-citation><mixed-citation xml:lang="en">Dodd KM, Yang J, Shen MH, et al. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene. 2015;34(17):2239-2250. doi: https://doi.org/10.1038/onc.2014.164.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Yu JS, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143(17):3050-3060.</mixed-citation><mixed-citation xml:lang="en">Yu JS, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143(17):3050-3060.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">doi: https://doi.org/10.1242/dev.137075.</mixed-citation><mixed-citation xml:lang="en">doi: https://doi.org/10.1242/dev.137075.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Hager M, Haufe H, Alinger B, Kolbitsch C. pS6 Expression in normal renal parenchyma, primary renal cell carcinomas and their metastases. Pathol Oncol Res. 2012;18(2):277-283. doi: https://doi.org/10.1007/s12253-011-9439-y.</mixed-citation><mixed-citation xml:lang="en">Hager M, Haufe H, Alinger B, Kolbitsch C. pS6 Expression in normal renal parenchyma, primary renal cell carcinomas and their metastases. Pathol Oncol Res. 2012;18(2):277-283. doi: https://doi.org/10.1007/s12253-011-9439-y.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Figlin RA, Kaufmann I, Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer. 2013;133(4):788-796. doi: https://doi.org/10.1002/ijc.28023.</mixed-citation><mixed-citation xml:lang="en">Figlin RA, Kaufmann I, Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer. 2013;133(4):788-796. doi: https://doi.org/10.1002/ijc.28023.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Thangavelu K, Pan CQ, Karlberg T, et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci U S A. 2012;109(20):7705-7710. doi: https://doi.org/10.1073/pnas.1116573109.</mixed-citation><mixed-citation xml:lang="en">Thangavelu K, Pan CQ, Karlberg T, et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci U S A. 2012;109(20):7705-7710. doi: https://doi.org/10.1073/pnas.1116573109.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36(6):320-328. doi: https://doi.org/10.1016/j.tibs.2011.03.006.</mixed-citation><mixed-citation xml:lang="en">Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36(6):320-328. doi: https://doi.org/10.1016/j.tibs.2011.03.006.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Darwish OM, Kapur P, Youssef RF, et al. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology. 2013;81(3):581-586. doi: https://doi.org/10.1016/j.urology.2012.11.030.</mixed-citation><mixed-citation xml:lang="en">Darwish OM, Kapur P, Youssef RF, et al. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology. 2013;81(3):581-586. doi: https://doi.org/10.1016/j.urology.2012.11.030.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Tanaka TN, Alloju SK, Oh DK, et al. Thyroid cancer: molecular pathogenesis, tyrosine kinase inhibitors, and other new therapies. Am J Hematol Oncol. 2015;11(4):5-9.</mixed-citation><mixed-citation xml:lang="en">Tanaka TN, Alloju SK, Oh DK, et al. Thyroid cancer: molecular pathogenesis, tyrosine kinase inhibitors, and other new therapies. Am J Hematol Oncol. 2015;11(4):5-9.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Jin S, Borkhuu O, Bao W, Yang YT. Signaling pathways in thyroid cancer and their therapeutic implications. J Clin Med Res. 2016;8(4):284-296. doi: https://doi.org/10.14740/jocmr2480w.</mixed-citation><mixed-citation xml:lang="en">Jin S, Borkhuu O, Bao W, Yang YT. Signaling pathways in thyroid cancer and their therapeutic implications. J Clin Med Res. 2016;8(4):284-296. doi: https://doi.org/10.14740/jocmr2480w.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184-199. doi: https://doi.org/10.1038/nrc3431.</mixed-citation><mixed-citation xml:lang="en">Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184-199. doi: https://doi.org/10.1038/nrc3431.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, Wang H, Xu J, et al. Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways. Toxicol Lett. 2014;228(3):248-259. doi: https://doi.org/10.1016/j.toxlet.2014.05.015.</mixed-citation><mixed-citation xml:lang="en">Zhang L, Wang H, Xu J, et al. Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways. Toxicol Lett. 2014;228(3):248-259. doi: https://doi.org/10.1016/j.toxlet.2014.05.015.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
